We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Switching from baricitinib to dupilumab as an advanced‐line treatment in pediatric patients with atopic dermatitis: a retrospective cohort study.
- Authors
Ollech, Ayelet; Cohen‐Barak, Eran; Horev, Amir; Bar‐Ilan, Efrat; Greenberger, Shoshana
- Abstract
This article discusses a retrospective cohort study that aimed to evaluate the effectiveness of switching from the JAK inhibitor baricitinib to the biological treatment dupilumab in pediatric patients with atopic dermatitis (AD). The study collected data from pediatric patients who had been treated with baricitinib for at least 6 months before switching to dupilumab. The study found that after switching to dupilumab, patients experienced positive outcomes, including complete response and partial response, with notable itch improvement. However, the study has limitations due to its small size and retrospective nature, and further research is needed to confirm the efficacy of dupilumab after JAK inhibitor failure in pediatric AD.
- Subjects
CHILD patients; ATOPIC dermatitis; PEDIATRIC therapy; BARICITINIB; DUPILUMAB
- Publication
International Journal of Dermatology, 2024, Vol 63, Issue 7, pe130
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.17198